This announcement is a separate document:
迈普医学：北京市中伦（广州）律师事务所关于广州迈普再生医学科技股份有限公司2024年限制性股票激励计划首次授予相关事项的法律意见书
Medprin Regenerative Medical Technologies: Legal opinion of Zhong Lun (Guangzhou) Law Firm regarding the first grant of Guangzhou HBMEDICINE Technology Co., Ltd.'s 2024 restricted stock incentive plan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.